Trastuzumab Deruxtecan
Daiichi Sankyo,AstraZeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 't-dxd', 'destiny,crc,02', 'deliver,(-delivered),(-delivery),(-delivers),(-delivering)']
destiny-crc02: t-dxd in her2+ crc showing activity in a heavily treated population, especially for her2 3+ by ihc. makes sense adc does not rely on sidedness or kras mutation... if the expression is there the drug can bind and deliver the chemotherapy dose #asco23 #crcsm 
GI Oncologist at @IUCancerCenter. @uw_hemeoncpc and @UChicagomed alum. Tweets are my own.